Seniors Turn to Cannabis as Doctors Push for Safety Protocols

Senior Adoption Rates Outpace Clinical Training

Cannabis use among Americans 65 and older has more than tripled since 2015, yet most primary-care physicians report receiving no formal training on cannabinoid therapeutics or geriatric dosing. The mismatch has left many older patients on their own, trying to figure out product selection, THC-to-CBD ratios, and potential drug interactions without professional guidance, according to geriatric pharmacology researchers interviewed by STAT.

Polypharmacy—the use of five or more prescription medications—is common in seniors. That raises the risk of adverse interactions with cannabis. Cannabinoids are metabolized by the cytochrome P450 enzyme system, the same pathway used by blood thinners, antidepressants, and statins.

Physicians Call for Harm-Reduction Framework

Medical societies are now urging a harm-reduction approach that treats cannabis like any other therapeutic agent requiring dosing precision, contraindication screening, and follow-up monitoring. The American Geriatrics Society hasn't issued formal cannabis prescribing guidelines, but individual academic medical centers have begun integrating cannabinoid consultations into pain-management and palliative-care workflows.

Doctors can no longer dismiss senior cannabis use as fringe behavior—it's mainstream, and clinical protocols must catch up to patient demand.

For full background on this demographic shift, see the CannIntel topic hub on seniors and cannabis use.

Drug Interaction Risks Drive Protocol Push

The most urgent clinical concern is cannabinoid interaction with warfarin, a blood thinner used by millions of older adults to prevent stroke. Case reports document elevated INR levels—a measure of blood-clotting time—in patients combining cannabis with warfarin, raising bleeding risk. Similar interactions have been observed with clopidogrel, SSRIs, and benzodiazepines.

Geriatricians recommend starting with low-dose CBD formulations, typically 5-10 mg per day, and titrating slowly while monitoring for side effects such as dizziness, sedation, or changes in appetite. THC products? They carry higher risk of cognitive impairment and falls in older adults.

What Clinicians and Patients Should Watch

Healthcare providers treating older cannabis users should document product type, cannabinoid ratios, dosing frequency, and any concurrent medications. Patients should be advised to purchase lab-tested products from licensed dispensaries to avoid contaminants and dosing inconsistencies common in unregulated markets.

What comes next matters. Will Medicare Advantage plans or private insurers cover cannabinoid consultations as part of chronic disease management? That coverage decision could determine whether evidence-based protocols reach the patients who need them most.